Alzheimer’s drug saga prompts journal to scrutinize whistle-blowers
Publication requires complainants to disclose financial conflicts in the wake of controversy over Cassava Sciences’ experimental treatment simufilam.
https://www.nature.com/articles/d41586-023-00050-z?utm_source=Nature+Briefing&utm_campaign=9e3739a111-briefing-dy-20230116&utm_medium=email&utm_term=0_c9dfd39373-9e3739a111-43576073
Comments
Post a Comment